TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company...
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company...
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024
TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Taysha Gene Therapies (NASDAQ:TSHA) just reported results for the second quarte...
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
Monday 7/1 Insider Buying Report: TSHA, AMSWA
Wednesday Sector Laggards: Music & Electronics Stores, Biotechnology Stocks
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?
Taysha Gene Therapies stock is down on Wednesday after the company announced a proposed public offering for TSHA shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing...
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization,...